Melanoma News and Research

Latest Melanoma News and Research

Study details the “immunometabolic editing” mechanism of tumor evolution

A Ludwig Cancer Research study has discovered that the immune system's surveillance of cancer can itself induce metabolic adaptations in the cells of early-stage tumors that simultaneously promote their growth and equip them to suppress lethal immune responses.

5 Jan 2023

Researchers identify novel gene mechanism in most aggressive kidney cancers

In a new study from the Johns Hopkins Kimmel Cancer Center, researchers described a novel mechanism of tumor formation in kidney cancers driven by overexpression of the mechanistic target of rapamycin complex 1 (mTORC1) signaling pathway with loss of the tuberous sclerosis complex (TSC) tumor suppressor gene.

3 Jan 2023

NCI-led clinical trial results in the first approval of a treatment for advanced alveolar soft part sarcoma

A clinical trial led by the National Cancer Institute (NCI), part of the National Institutes of Health, has resulted in the first approval of a treatment for advanced alveolar soft part sarcoma (ASPS).

28 Dec 2022

Phase I clinical trial of PAC-1 in patients with end-stage cancers shows promising results

A phase I clinical trial of PAC-1, a drug that spurs programmed cell death in cancer cells, found only minor side effects in patients with end-stage cancers.

22 Dec 2022

Extracellular vesicles enhance cancer immunotherapy

Nano-sized membrane bubbles known as extracellular vesicles activate the immune system in mice and seem to render their tumors sensitive to a type of immunotherapy drug called a checkpoint inhibitor.

22 Dec 2022

New method uses artificial DNA to target and kill cancer cells

Researchers at the University of Tokyo have used artificial DNA to target and kill cancer cells in a completely new way.

21 Dec 2022

BGI cares - 2022 social responsibilities in review

At BGI Genomics, we believe it is our responsibility to not only enhance global health outcomes, but also to help make the places we work and live in better.

From BGI Genomics 20 Dec 2022

Immune-evading Mycobacterium tuberculosis prevents inflammatory responses by hijacking the host’s ubiquitin

A new study discussed the findings of Chai et al., which revealed that triple specificity protein phosphatase (ptpB) secreted by Mycobacterium tuberculosis inhibits pyroptosis and the release of cytokines by macrophages, allowing M. tuberculosis to invade the immune system.

19 Dec 2022

CU study proves effectiveness of new multidrug treatment for patients with stage IV melanoma

A new multidrug treatment for patients with stage IV melanoma has proven effective after a three-year clinical trial at the University of Colorado Cancer Center.

16 Dec 2022

Novel immunotherapy offers a promising new strategy to fight hard-to-treat cancers

Scientists at UC San Francisco have engineered T cells to produce a potent anti-cancer cytokine, but only when they encounter tumor cells.

16 Dec 2022

Using synthetic gene circuits to better control the timing of immunotherapy

In two separate studies, researchers demonstrate how synthetic biology can be used to tackle a difficult issue in cancer immunotherapy: the way immunotherapy-related approaches focused on short-term killing of tumor cells may fail to eradicate tumors because growth of tumors happens on longer timescales.

16 Dec 2022

Study may allow patients with multiple breast lesions to consider breast-conserving therapy as treatment option

Patients with multiple tumors in the same breast who underwent a lumpectomy followed by radiation therapy had local recurrence rates comparable to those historically observed in patients with a single tumor, according to results from the ACOSOG Z11102 (Alliance) prospective phase II clinical trial, which were presented at the San Antonio Breast Cancer Symposium, held December 6-10, 2022.

9 Dec 2022

Melanoma News and Research

Latest Melanoma News and Research

Study details the “immunometabolic editing” mechanism of tumor evolution

Researchers identify novel gene mechanism in most aggressive kidney cancers

NCI-led clinical trial results in the first approval of a treatment for advanced alveolar soft part sarcoma

Phase I clinical trial of PAC-1 in patients with end-stage cancers shows promising results

Extracellular vesicles enhance cancer immunotherapy

New method uses artificial DNA to target and kill cancer cells

BGI cares - 2022 social responsibilities in review

Immune-evading Mycobacterium tuberculosis prevents inflammatory responses by hijacking the host’s ubiquitin

CU study proves effectiveness of new multidrug treatment for patients with stage IV melanoma

Novel immunotherapy offers a promising new strategy to fight hard-to-treat cancers

Using synthetic gene circuits to better control the timing of immunotherapy

Study may allow patients with multiple breast lesions to consider breast-conserving therapy as treatment option

Cancer immunotherapies can become more potent depending on the time of day

Wearable technology could improve doctors' ability to administer precise medication doses

The potential of grape consumption to modulate UV-induced skin erythema

Detection of filoviruses by the innate immune system

New study points to a strategy for inhibiting hyper-progression of melanoma

High-risk stage III-IV melanoma patients treated with pembrolizumab report better quality of life

Single drug compound may offer a promising new strategy for treating prostate cancer patients

Over 440 SCI articles published! BGI’s cancer genetics and cell research fuels innovation

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Melanoma News and Research

Latest Melanoma News and Research

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Newsletters you may be interested in